PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway

Chen,Wenli; Dai,Guangli; Qian,Yike; Wen,Lian; He,Xueqing; Liu,Hui; Gao,Yunxing; Tang,Xingli; Dong,Bohan

doi:10.3892/or.2021.8222

PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway

Authors:
- Wenli Chen
- Guangli Dai
- Yike Qian
- Lian Wen
- Xueqing He
- Hui Liu
- Yunxing Gao
- Xingli Tang
- Bohan Dong
View Affiliations

Affiliations: Department of Biochemistry, Wannan Medical College, Wuhu, Anhui 241002, P.R. China, Department of Obstetrics and Gynecology, Wuhu Traditional Chinese Medicine Hospital, Wuhu, Anhui 241003, P.R. China, Department of Pharmacy, Wannan Medical College, Wuhu, Anhui 241002, P.R. China, Department of Microbiology and Immunology, Wannan Medical College, Wuhu, Anhui 241002, P.R. China
Published online on: November 9, 2021 https://doi.org/10.3892/or.2021.8222
Article Number: 11

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The phosphatidylinositol‑3‑kinase catalytic subunit α (PIK3CA) gene is mutated in numerous human cancers. This mutation promotes the proliferation of tumor cells; however, the underlying mechanism is still not clear. In the present study, it was revealed that the PIK3CA mutation in colorectal cancer (CRC) HCT116 (MUT) rendered the cells more dependent on glutamine by regulating the glutamic‑pyruvate transaminase 2 (GPT2). The dependence of glutamine increased the proliferation of cells in a normal environment and resistance to a suboptimal environment. Further study revealed that the mutated PIK3CA could regulate GPT2 expression not only through signal transduction molecule 3‑phosphoinositide‑dependent kinase (PDK1) but also through mitogen‑activated protein kinase (MEK) molecules. In HCT116 cells, MEK inhibitor treatment could reduce the expression of GPT2 signaling molecules, thereby inhibiting the proliferation of CRC cells. A new signal transduction pathway, the PI3K/MEK/GPT2 pathway was identified. Based on these findings, MEK and PDK1 inhibitors were combined to inhibit the aforementioned pathway. It was revealed that the combined application of MEK and PDK1 inhibitors could promisingly inhibit the proliferation of MUT compared with the application of PI3K inhibitors, PDK1 inhibitors, or MEK inhibitors alone. In vivo, MEK inhibitors alone and combined inhibitors had stronger tumor‑suppressing effects. There was no significant difference between the PDK1‑inhibitor group and normal group in vivo. Thus, these results indicated that mutated PI3K affected GPT2 mediated by the MEK/PDK1 dual pathway, and that the PI3K/MEK/GPT2 pathway was more important in vivo. Inhibiting MEK and PDK1 concurrently could effectively inhibit the proliferation of CRC cells. Targeting the MEK and PDK1 signaling pathway may provide a novel strategy for the treatment of PIK3CA‑mutated CRC.

View Figures

View References

1	Han Y, Peng Y, Fu Y, Cai C, Guo C, Liu S, Li Y, Chen Y, Shen E, Long K, et al: MLH1 deficiency induces cetuximab resistance in colon cancer via Her-2/PI3K/AKT Signaling. Adv Sci (Weinh). 7:20001122020. View Article : Google Scholar : PubMed/NCBI
2	Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, et al: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 7:561–573. 2005. View Article : Google Scholar : PubMed/NCBI
3	Spandidos DA and Wilkie NM: Malignant transformation of early passage rodent cells by a single mutated human oncogene. Nature. 310:469–475. 1984. View Article : Google Scholar : PubMed/NCBI
4	Durrant TN and Hers I: PI3K inhibitors in thrombosis and cardiovascular disease. Clin Transl Med. 9:82020. View Article : Google Scholar : PubMed/NCBI
5	Mazloumi Gavgani F, Smith Arnesen V, Jacobsen RG, Krakstad C, Hoivik EA and Lewis AE: Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β isoforms in endometrial cancer. Int J Mol Sci. 19:39312018. View Article : Google Scholar : PubMed/NCBI
6	Blackburn PR, Milosevic D, Marek T, Folpe AL, Howe BM, Spinner RJ and Carter JM: PIK3CA mutations in lipomatosis of nerve with or without nerve territory overgrowth. Mod Pathol. 33:420–430. 2020. View Article : Google Scholar : PubMed/NCBI
7	Murakami K, Kanto A, Sakai K, Miyagawa C, Takaya H, Nakai H, Kotani Y, Nishio K and Matsumura N: Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma. Mod Pathol. doi: https://doi.org/10.1101/2021.02.25.432943. 2021. View Article : Google Scholar
8	Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J and DeCensi A: PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. A systematic review and meta-analysis of epidemiological studies. Clin Oncol (R Coll Radiol). 28:317–326. 2016. View Article : Google Scholar
9	Tzanikou E, Markou A, Politaki E, Koutsopoulos A, Psyrri A, Mavroudis D, Georgoulias V and Lianidou E: PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: A direct comparison study. Mol Oncol. 13:2515–2530. 2019. View Article : Google Scholar : PubMed/NCBI
10	Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K, et al: Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65:4562–4567. 2005. View Article : Google Scholar : PubMed/NCBI
11	Ghodsinia AA, Lego JMT and Garcia RL: Mutation-associated phenotypic heterogeneity in novel and canonical PIK3CA helical and kinase domain mutants. Cells. 9:11162020. View Article : Google Scholar : PubMed/NCBI
12	Sun B, Jiang Y, Cui H, Fang X, Han G, Dai X, Zhou S, Mao H and Wang B: Activating PIK3CA mutation promotes adipogenesis of adipose-derived stem cells in macrodactyly via up-regulation of E2F1. Cell Death Dis. 11:6002020. View Article : Google Scholar : PubMed/NCBI
13	Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, et al: Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science. 366:714–723. 2019. View Article : Google Scholar : PubMed/NCBI
14	Hong X, Zhong L, Xie Y, Zheng K, Pang J, Li Y, Yang Y, Xu X, Mi P, Cao H, et al: Matrine reverses the Warburg effect and suppresses colon cancer cell growth via negatively regulating HIF-1α. Front Pharmacol. 10:14372019. View Article : Google Scholar : PubMed/NCBI
15	Momi N, Wali RK, Chhaparia A, Calderwood AH, Tiwari A, Ledbetter SE, DeLaCruz M and Roy HK: Su2000 PRDM16 is a novel proto-oncogene in colorectal cancer (CRC): Modulation of the early Warburg effect in field carcinogenesis. Gastroenterology. 150 (Suppl):S6062016. View Article : Google Scholar
16	Giuliani N, Chiu M, Bolzoni M and Bussolati O: Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage. Transl Cancer Res. 5 (Suppl 4):S885–S888. 2016. View Article : Google Scholar
17	Hao Y, Samuels Y, Li Q, Krokowski D, Guan BJ, Wang C, Jin Z, Dong B, Cao B, Feng X, et al: Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nat Commun. 7:119712016. View Article : Google Scholar : PubMed/NCBI
18	Feng X, Hao Y and Wang Z: Targeting glutamine metabolism in PIK3CA Mutant colorectal cancers. Genes Dis. 3:241–243. 2016. View Article : Google Scholar : PubMed/NCBI
19	Kim M, Gwak J, Hwang S, Yang S and Jeong SM: Mitochondrial GPT2 plays a pivotal role in metabolic adaptation to the perturbation of mitochondrial glutamine metabolism. Oncogene. 38:4729–4738. 2019. View Article : Google Scholar : PubMed/NCBI
20	Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, Ron D, Parada LF and Karsenty G: ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab. 4:441–451. 2006. View Article : Google Scholar : PubMed/NCBI
21	Slattery ML, Lundgreen A, Herrick JS and Wolff RK: Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. Mutat Res. 706:13–20. 2011. View Article : Google Scholar : PubMed/NCBI
22	Qiu Q, Jiang J, Lin L, Cheng S, Xin D, Jiang W, Shen J and Hu Z: Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways. Int J Oncol. 48:2508–2520. 2016. View Article : Google Scholar : PubMed/NCBI
23	Tserga A, Chatziandreou I, Michalopoulos NV, Patsouris E and Saetta AA: Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. Virchows Arch. 469:35–43. 2016. View Article : Google Scholar : PubMed/NCBI
24	Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, Lin NU, Krop IE, Roberts TM, et al: PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 35:2961–2970. 2016. View Article : Google Scholar : PubMed/NCBI
25	Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, et al: P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene. 34:3968–3976. 2015. View Article : Google Scholar : PubMed/NCBI
26	Toth K, Kuppuswamy M, Shashkova EV, Spencer JF and Wold WS: A fully replication-competent adenovirus vector with enhanced oncolytic properties. Cancer Gene Ther. 17:761–770. 2010. View Article : Google Scholar : PubMed/NCBI
27	Yano S, Takehara K, Miwa S, Kishimoto H, Tazawa H, Urata Y, Kagawa S, Bouvet M, Fujiwara T and Hoffman RM: In vivo isolation of a Highly-aggressive variant of Triple-negative human breast cancer MDA-MB-231 using serial orthotopic transplantation. Anticancer Res. 36:3817–3820. 2016. View Article : Google Scholar : PubMed/NCBI
28	Singleton DC and Harris AL: Targeting the ATF4 pathway in cancer therapy. Expert Opin Ther Targets. 16:1189–1202. 2012. View Article : Google Scholar : PubMed/NCBI
29	Juliana CA, Yang J, Cannon CE, Good AL, Haemmerle MW and Stoffers DA: A PDX1-ATF transcriptional complex governs β cell survival during stress. Mol Metab. 17:39–48. 2018. View Article : Google Scholar : PubMed/NCBI
30	Aoki M and Fujishita T: Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 407:153–189. 2017.PubMed/NCBI
31	Lien EC, Dibble CC and Toker A: PI3K signaling in cancer: Beyond AKT. Curr Opin Cell Biol. 45:62–71. 2017. View Article : Google Scholar : PubMed/NCBI
32	Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M, et al: PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc Natl Acad Sci USA. 110:21124–21129. 2013. View Article : Google Scholar : PubMed/NCBI
33	Salles B, Calsou P, Frit P and Muller C: The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy. Pathol Biol (Paris). 54:185–193. 2006. View Article : Google Scholar : PubMed/NCBI
34	Bartalucci N, Guglielmelli P and Vannucchi AM: Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 13 (Suppl 2):S307–S309. 2013. View Article : Google Scholar : PubMed/NCBI
35	Bao HR, Chen JL, Li F, Zeng XL and Liu XJ: Relationship between PI3K/mTOR/RhoA pathway-regulated cytoskeletal rearrangements and phagocytic capacity of macrophages. Braz J Med Biol Res. 53:e92072020. View Article : Google Scholar : PubMed/NCBI
36	Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B, et al: Measurement of PIP Levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell. 27:97–108. 2015. View Article : Google Scholar : PubMed/NCBI